New York is currently home to 4600 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
Recruiting
This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders
Gender:
All
Ages:
4 years and above
Trial Updated:
04/10/2022
Locations: The Skin Center Dermatology Group, New City, New York
Conditions: Actinic Keratosis, Verruca Plana, Tinea, Molluscum Contagiosum, Bowen's Disease, Warts, Acne/Rosacea
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Recruiting
Combination of analgesics with different modes of action have the potential to offer enhanced pain relief with reduced dosage. Ibuprofen and acetaminophen have different modes of action. Combination of ibuprofen and acetaminophen has shown enhanced analgesia in adult studies, with pediatric data limited to post-operative pain and dental pain. Our study objective is to evaluate the analgesic efficacy of oral acetaminophen plus ibuprofen versus ibuprofen plus placebo for the management of acute pa... Read More
Gender:
All
Ages:
Between 3 years and 20 years
Trial Updated:
04/07/2022
Locations: Jacobi Medical Center, Bronx, New York
Conditions: Pain, Acute
Novel Form of Acquired Long QT Syndrome
Recruiting
The goal of this study is to determine whether anti-Ro/SSA antibodies are associated with acquired QT prolongation in subjects with connective tissue disease. The investigators will investigate whether gender or race influence correlation between anti-Ro antibody status and prolonged QT interval and the role of inflammatory cytokines in association with anti-Ro antibodies and QT prolongation. The investigators propose to add an additional objective to test whether QT prolongation is reversible w... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
04/07/2022
Locations: VA New York Harbor Healthcare System, NY and Brooklyn Campuses, New York, New York
Conditions: Long QT Syndrome, Connective Tissue Diseases, Rheumatoid Arthritis
The Leukemia and Lymphoma Society (LLS) National Research Registry
Recruiting
The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/05/2022
Locations: Lymphoma and Leukemia Society, Rye Brook, New York
Conditions: Blood Cancer
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: VA Bronx, Bronx, New York
Conditions: End Stage Liver Disease
Myeloproliferative Neoplasms (MPN) and COVID-19
Recruiting
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2022
Locations: New York-Presbyterian/Weill Cornell Medical Center, New York, New York
Conditions: Myeloproliferative Neoplasm, COVID
Manual Therapy in Addition to Pulmonary Rehabilitation in Moderate Chronic Obstructive Pulmonary Disease.
Recruiting
The aim of this study is to investigate the feasibility of administering this combination of interventions (CMT plus PR) to Veterans with moderate COPD within the context of a hospital-based outpatient pulmonary rehabilitation program.
Gender:
All
Ages:
Between 50 years and 70 years
Trial Updated:
03/29/2022
Locations: Syracuse VA Medical Center, Syracuse, New York
Conditions: Chronic Obstructive Pulmonary Disease Moderate
The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey
Recruiting
A cross-sectional descriptive survey of the BOLD for individuals after having been ill with COVID-19 or have taken the COVID-19 vaccine will be compared with that of individuals who have neither been ill with COVID-19 nor taken the COVID-19 vaccine. Individuals who have both been ill and taken the COVID-19 vaccine will be compared to identify any additive risk factors.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/28/2022
Locations: Daniel Cameron, Mount Kisco, New York
Conditions: COVID-19, Lyme Disease, COVID-19 Vaccine
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Recruiting
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2022
Locations: NYU Langone Nephrology Associates, Mineola, New York
Conditions: Glomerular Disease, Proteinuria
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Recruiting
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single product with the two components of PSB202 enabling a distinct dual target-specific antibody directed cell killing of B-cells. Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with indolent-, relapsed-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2022
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
Non Exudative AMD Imaged With SS-OCT- Extension
Recruiting
The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the CC could prove useful as an anatomic clinical trial endpoint in future drug trials.
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Vitreous Retina Macular Consultants of NY, New York, New York
Conditions: Dry Macular Degeneration
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Coronary Artery Disease